Canagliflozin, (marketed under the brand names Invokana or Sulisent) is one of the sodium glucose cotransporter 2 (SGLT-2) inhibitor class of drugs. Introduced relatively recently, these drugs have been widely studied for both their potential complications (kidney issues and amputation risk), and potential benefits for heart health. Now the CANVAS study finds canagliflozin significantly reduces risk for cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with type 2 diabetes when compared to placebo. Read more